Additionally, beyond adapting existing drug combinations, cutting-edge therapies such as bispecific antibodies and CAR T-cell ...

QBS72S, a LAT1-targeted agent, shows potential in treating leptomeningeal disease, improving survival rates in metastatic ...

LP-184 shows promising efficacy and safety in heavily pretreated advanced cancer patients, paving the way for innovative ...

JANX007 shows significant PSA reductions and favorable rPFS in mCRPC patients, with a manageable safety profile. The trial identifies 6 mg and 9 mg as optimal doses, balancing safety and efficacy.

Targeted Therapies in Oncology provides evidence-based news and updates on the most current advances in therapeutics, biomarkers, pathways, biomarkers, molecular profiling, and diagnostic testing with ...

As Dr Voorhees mentioned in part 2, the definition of high-risk SMM has evolved over time and is subject to change in the ...

The FDA has granted traditional approval to pirtobrutinib (Jaypirca) for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma ...

IGV-001, an investigational autologous cell immunotherapeutic combination product, may offer clinically meaningful overall ...

Dr. Peter Voorhees discusses groundbreaking AQUILA study results, highlighting daratumumab's significant impact on high-risk ...

Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.

Sacituzumab tirumotecan demonstrated a 31% objective response rate and 71% disease control rate in advanced urothelial ...

Ipatasertib showed significant activity in patients with AKT1E17K mutations, with a 24.1% objective response rate and a median response duration of 10.1 months. The trial's 6-month progression-free ...